(NASDAQ: ATRA) Atara Biotherapeutics's forecast annual revenue growth rate of -3.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Atara Biotherapeutics's revenue in 2026 is $23,139,000.On average, 6 Wall Street analysts forecast ATRA's revenue for 2026 to be $6,047,267, with the lowest ATRA revenue forecast at $4,556,264, and the highest ATRA revenue forecast at $7,568,544. On average, 6 Wall Street analysts forecast ATRA's revenue for 2027 to be $290,875,383, with the lowest ATRA revenue forecast at $273,729,025, and the highest ATRA revenue forecast at $305,579,983.
In 2028, ATRA is forecast to generate $111,392,756 in revenue, with the lowest revenue forecast at $73,288,739 and the highest revenue forecast at $150,812,259.